7.13
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ
NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace
Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph
Amneal Boruzu Subcutaneous Formulation Launch - Clinical Oncology News
Amneal Earnings Preview: Key Updates Coming May 2 in Q1 2025 Report - Stock Titan
Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace
Amneal Announces New Data From Phase 3 Study - MarketScreener
Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com
Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan
Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S. - BioSpace
Amneal gets expanded coverage for Parkinson’s disease drug - Seeking Alpha
Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson'S Disease Patients In The U.S. - marketscreener.com
Breakthrough: Amneal's Parkinson's Drug CREXONT Secures Game-Changing Insurance Coverage - Stock Titan
Amneal and Shilpa introduce Boruzu in US for cancer treatment - Yahoo Finance
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - The Joplin Globe
Amneal Launches BORUZU , First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire
Groundbreaking Cancer Treatment: First Ready-Made Bortezomib Injection Hits Market - Stock Titan
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk) - Business Wire
Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR
Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - simplywall.st
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK
Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace
Amneal to Participate at Upcoming Investor Conference - WICZ
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com India
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Canada
Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com
Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com
Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com
Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):